Abstract: Machine logic (for example, software) for registering multiple medical images, each showing a common lesion, with each other. In performing this registration, registration points are chosen to be both: (i) outside of image portion that is potentially compromised by the lesion (in any of the multiple images); and (ii) as close to the lesion as possible. However, in at least one of the images the extent of the lesion is not known—so, in order to accommodate this uncertainty about the lesion boundaries, lesion predicting machine logic rules are used to predict the size, shape and/or location of the lesion. Machine learning is used to intermittently adjust and improve the lesion predicting machine logic rules.

Abstract: Embodiments of the present disclosure provide for systems of enhancing the signal to noise ratio, methods of orienting a nanomaterial (e.g., an antibody), methods of enhancing the signal to noise ratio in a system (e.g., an assay system), and the like.

Abstract: The invention provides recombinant adenovirus (rAd) and rAd vectors comprising a bidirectional mouse CMV (mCMV) promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction. The invention also provides methods of making and using such rAd and rAd vectors.

Abstract: There has been a demand for a novel antisense nucleic acid or the like capable of inhibiting myostatin at the mRNA level. The present invention provides a specific antisense oligomer which allows exon 2 skipping in the myostatin gene or induces degradation of mRNA of the myostatin gene.

Abstract: Genetically modified mice and methods and compositions for making and using the same are provided, wherein the genetic modification comprises humanization of an Fc?RI protein.

Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring hyaluronic acid, death receptor 5, and/or transforming growth factor ?1 can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury.

Abstract: This invention relates to novel compositions comprising analogs of naturally occurring polypeptides, wherein the analog comprises an ?-amino acid and at least one ?-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.

Abstract: Disclosed is a vector pair for screening tau oligomer formation, a mouse embryo introduced with the vector pair, a transgenic model mouse of neurological disease, obtained from the mouse embryo, and a method of screening a tau oligomer formation inhibitor candidate using the transgenic model mouse. More specifically, the present invention provides vector pair for screening tau oligomer formation, comprising: a first vector comprising a first tau gene, a first fluorescence protein gene and a first neuron-specific promoter; and a second vector comprising a second tau gene, a second fluorescence protein gene and a second neuron-specific promoter, wherein a protein expressed from the first fluorescence protein gene and a protein expressed from the second fluorescence protein gene bind to each other to display fluorescence, by association between a protein expressed from the first tau gene and a protein expressed from the second tau gene.

Abstract: Methods are provided for monitoring a subject having a graft for an acute rejection (AR) response, e.g., to predict, to diagnose, and/or to characterize an AR response. In practicing the subject methods, the expression level of at least one gene in a sample from the subject, e.g., a blood or biopsy sample, is evaluated, e.g., at the nucleic acid and/or protein level, to monitor the subject. Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods.

Abstract: There is disclosed a process and an array for assaying for binding of target molecules to capture molecules on micro array devices, wherein the microarray devices contain electrodes. Specifically, there is disclosed a binding (including nucleotide hybridization) process to detect binding on a microarray wherein the microarray contains electronically addressable electrode devices. There is further disclosed an enzymatically catalyzed oxidation/reduction reaction to take place within a “virtual flask” region of a micro array wherein the reaction is detected by current changes detected on the addressable electrode.

Abstract: This disclosure provides an integrated and automated sample-to-answer system that, starting from a sample comprising biological material, generates a genetic profile in less than two hours. In certain embodiments, the biological material is DNA and the genetic profile involves determining alleles at one or a plurality of loci (e.g., genetic loci) of a subject, for example, an STR (short tandem repeat) profile, for example as used in the CODIS system. The system can perform several operations, including (a) extraction and isolation of nucleic acid; (b) amplification of nucleotide sequences at selected loci (e.g., genetic loci); and (c) detection and analysis of amplification product. These operations can be carried out in a system that comprises several integrated modules, including an analyte preparation module; a detection and analysis module and a control module.

Abstract: The present invention relates to the field of seizures. More specifically, the present invention provides compositions and methods for treating refractory seizures in neonates. In one embodiment, the method comprises the steps of (a) administering to the patient an amount of a KCC2 agonist and/or trkB antagonist effective to restore KCC2 expression to normal physiological levels; and (b) administering to the patient an effective amount of an anti-seizure medication.

Abstract: The present invention pertains to methods for determining the change in the immune repertoire of an individual suffering from disease or undergoing therapy for the treatment of a disease. The methods use the difference between the change in the level of immune cell diversity seen in an individual before, during or after a health event to determine the effect of the disease, or the effect of a treatment regime, on the individual. The difference in the level of immune cell diversity is referred to as the Delta Index and is defined as the quantitative and qualitative change (gain or loss of clones) of an individual's most dynamic immune cells over time.

Abstract: In a method and arrangement for detecting binding events of molecules, at least one second molecule covalently bound to a ligand, and optionally bonded to a third molecule bound to a ligand, forms a specific non-covalent fond with a first molecule immobilised on a bioactive surface by a covalent bond, and binding events between an analyte molecule and the second-molecule bound ligand are detected by an analytical measuring method, wherein the specific non-covalent bond between the first and second molecules is breakable by supplying a buffer solution, and, hence, a specific ligand, or two, different specific ligands are made available on the bioactive surface in an easily reversible manner.

Abstract: Provided herein are methods of treating, preventing, ameliorating or managing a nonsense mutation mediated epileptic disease, comprising administering a 1,2,4-oxadiazole benzoic acid to a patient having a nonsense mutation mediated epileptic disease. In particular, provided herein are methods of treating, preventing, ameliorating or managing a CDKL5 and/or SCN1A (Dravet syndrome) nonsense mutation mediated epileptic disease.

Abstract: A system and method for the label-free analysis of cells includes a purification device configured to receive a heterogeneous population of cells, the purification device temporarily trapping therein a subpopulation of cells from the heterogeneous population of cells and a cell analysis device positioned downstream of the purification device and configured to measure one or more cellular parameters including cell count, measured cell size, and/or cell morphology. In an alternative embodiment, the subpopulation of cells is analyzed while they are trapped within the purification device.

Abstract: The invention relates to a method and a device for optical in vitro detection of a movement in a biological sample with a spatial extent in the form of a three-dimensional cell and/or tissue culture or a cell cluster or a sample made of freely swimming microorganisms.

Abstract: The present invention relates to methods of quantifying nucleic acids involving (a) contacting a sample to be tested with whole-genome amplification (WGA) reaction components and a dye molecule to form a reaction sample, wherein the dye molecule detects the nucleic acid; (b) partitioning the reaction sample wherein each partitioned reaction sample corresponds to a single reaction; (c) allowing the reaction to occur in the partitioned reaction sample and (d) determining the number of partitioned reaction samples having the dye molecule, wherein the dye molecule indicates the presence of the nucleic acid; thereby quantifying the nucleic acid in the sample to be tested.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to biomarkers associated with CTCL, including TOX, PLS3, KIR3DL2, GATA3 and RUNX3, where increased expression, relative to normal control, of one or more of TOX, PLS3, KIR3DL2, and/or GATA3 is associated with CTCL and decreased expression of RUNX3, relative to normal control, is associated with CTCL. One or more of these biomarkers may be used to diagnose CTCL and/or design and monitor treatment.

Abstract: The present invention relates to the field of biopharmaceuticals, and in particular to a protein, a protein conjugate, a pharmaceutical composition and its use for treating diabetes. The fusion protein of the present invention is obtained by linking two polypeptides, wherein one polypeptide is an interleukin-1 receptor antagonistic protein or an analogue thereof, and another polypeptide is GLP-1 receptor binding polypeptide or an analogue thereof, or an insulin receptor binding polypeptide or an analogue thereof, or a GIP receptor binding polypeptide or an analogue thereof. The fusion proteins of the present invention and conjugates thereof have a significant efficacy in treating diabetes, and can be used in a lower dose, resulting in marked reduction in side effects.

Abstract: Disclosed herein are methods and compositions for detecting Bordetella pertussis and Bordetella parapertussis by detecting the presence of the IS481 and IS1001 genomic insertion sequences, respectively.

Abstract: A computer-implemented method, system, and apparatus for providing interactive and analytical components that provide a comprehensive and dynamic tool for therapies to prevent and cure dementia-related diseases. The invention includes one or more computers that receive and store personal information for people, including personal background information, pre-existing conditions, current medications, genomic data and diagnostic information. The computers also generate synergic data containing compounded probability data specifying an expected adjustment of individual biological mechanisms from particular combinations of therapies. For each person, the computers process personal information and identify a subset of biological mechanisms that are principally affected by dementia-related diseases or the substantial risk of dementia-related diseases.

Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Down Syndrome Gene, in particular, by targeting natural antisense polynucleotides of a Down Syndrome Gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Down Syndrome Genes.

Abstract: The disclosure relates to a virus-like particle in which a protein complex is entrapped, ensuring the formation of the protein complex under physiological conditions, while protecting the protein complex during purification and identification. The disclosure further relates to the use of such virus-like particle for the isolation and identification of protein complexes.

Abstract: The invention relates generally to new prostate cancer markers, and particularly to a class of cancer marked by the presence of missense mutations in SPOP, an E3 ubiquitin ligase component. The invention provides methods and materials for detecting and diagnosing prostate cancer by detecting these mutations and may be useful in predicting disease progression and response to therapy.

Abstract: The invention provides an isolated, purified population of human cells comprising CD8+ T cells with reduced Cbl-b activity. The invention provides uses of such cells in methods for inducing or enhancing an anti-tumor immune response in a subject. These methods comprise: (a) providing a cell population, from a subject or from another source, which comprises CD8+ T cells, (b) reducing Cbl-b activity in the CD8+ T-cells, (c) administering the cells of step (b) to the subject. The invention provides methods for making CD8+ T cells that do not require stimulation through a co-receptor in order for the cell to become activated or proliferated in response to contact via its T cell receptor. Such methods are based upon reducing function of Cbl-b. The invention also provides methods for identifying agents which affect Cbl-b expression or activity.

Abstract: Embodiments of the present invention provide methods, computer program products, and systems for classification and identification of cancer genes while correcting for sample bias for tumor-derived genomic features as well as other biased features using machine learning techniques. Embodiments of the present invention can be used to receive a set of genes that include a first gene and a subset of synthetic genes that include similar features to the first gene and receive a set of gene labels associated with physiological characteristics. Embodiments of the present invention can estimate probabilities that genes in the set of genes are associated with gene labels in the set of gene labels using a machine learning classifier and estimate an effective probability range for the first gene and each gene label based, at least in part, on the first gene's estimated probabilities and the estimated probabilities of one or more of the synthetic genes.

Abstract: A multiplex slide plate device and an operation method thereof are provided. The multiplex slide plate device includes a slide plate and a sacrificial layer. The slide plate has reaction vessels arranged in an array, wherein each of the reaction vessels has an opening portion and a bottom portion. The sacrificial layer has a microfluidic channel, wherein the microfluidic channel has an injection channel, a main channel and a distal channel connected to each other. The sacrificial layer is assembled to the slide plate, wherein the main channel faces the opening portion. A sample solution is injected into the injection channel, such that the sample solution flows from the injection channel through the main channel to the distal channel, wherein the sample solution loads into each of the reaction vessels while flowing through the main channel.

Abstract: The invention relates to vectors and mammalian cells in a system useful for switching on or switching off gene expression in response to fatty acids, and a method of treating diet-induced obesity. In particular, a synthetic intracellular lipid-sensing receptor was constructed that constantly monitors blood fatty acid levels, processes diet-associated hyperlipidemia and coordinates reversible and adjustable expression of the anorectic peptide hormone pramlintide to reduce dietary intake, blood fat levels and body weight.

Abstract: This disclosure relates to systems and methods for communicating and storing data that may include genomic data. In certain embodiments, a sample genome may be stored and/or communicated as a list of variants relative to a reference dataset. Transmission and/or storage of a set of variants relative to a reference genome may allow for more efficient storage and/or communication of the sample genome. Systems and methods are further disclosed that allow for the efficient selection and computation of a reference dataset used to represent a set of sample genomes.

Abstract: An in vitro method for the diagnosis, prognosis, stratification and/or monitoring of colorectal cancer in a subject includes detecting the level of AREG, CEA, HGF-receptor, ErbB4-Her4, CD69, PSA, EMMPRIN, and INF-gamma biomarkers in a biological sample of the subject. In an embodiment, the subject is administered a treatment when a differential level of the biomarkers compared to a healthy control or a reference value is indicative for the presence of colorectal cancer in the subject.

Abstract: The present invention discloses the active substances for preventing hearing deterioration, its preparation method, the pharmaceutical composition containing the active substances, and the preparation method of the pharmaceutical composition. The preparation method of the active substances is performed by plate cultivation, flask cultivation and fermentation tank cultivation, to obtain the active substances of Hericium erinaceus mycelia in powder form. The powder of H. erinaceus mycelia is proved to have the effect of preventing hearing deterioration.

Abstract: An adaptor for use in amplifying all linear, double-stranded nucleic acid molecules of unknown sequences in a sample is disclosed. The adaptor consists of: (1) the first oligonucleotide (P-oligo) with a phosphate at the 5? end and without an additional thymine nucleotide at the 3? end; and (2) the second oligonucleotide (T˜oligo) with an extra 3?-T and without a 5?-phosphate. The P-oligo and T-oligo are complementary to each other except at the 3?-T (thymine) in the T-oligo. The adaptor is ligated to nucleic acids of unknown sequences which have an extra A in the 3? end (3?˜A overhang) to form adaptor-ligated target nucleic acids. The T-oligo is then employed as a single primer for T-oligo-primed polymerase chain reaction (TOP-PCR) and amplifies the nucleic acids of unknown sequences in full-length.

Abstract: The present invention provides methods for diagnosing melanoma and/or solar lentigo in a subject by analyzing nucleic acid molecules obtained from the subject. The present invention also provides methods for distinguishing melanoma from solar lentigo and/or dysplastic nevi and/or normal pigmented skin. The methods include analyzing expression or mutations in epidermal samples, of one or more skin markers. The methods can include the use of a microarray to analyze gene or protein profiles from a sample.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to methods and compositions for identifying, selecting and/or producing an SDS tolerant soybean plant or germplasm. A soybean plant or germplasm that has been identified, selected and/or produced by any of the methods of the present invention is also provided. SDS tolerant soybean seeds, plants and germplasms are also provided.

Abstract: Nanoconjugates that include a polymalic-based molecular scaffold with one or more imaging moiety and one or more targeting modules attached to the scaffold are provided. Methods of targeting a diseased cell or a diseased tissue in a subject by administering the nanoconjugate are described. Methods of synthesizing the nanoconjugate are also provided.

Abstract: The present disclosure describes the generation and the use of Ad variants (Ad) possessing any combination of mutations in genes that code for the hexon, penton, fiber, and non-structural proteins, where simultaneous modification of hexon and penton are made to avoid the trapping of Ad in the liver and to reduce toxicity after intravascular virus administration. Such liver de-targeted Ad can be useful tool for selective and specific gene delivery to extra-hepatic tissues and cells, including disseminated metastatic cancer cells.

Abstract: Aspects of the invention include methods and compositions for microbial enhanced oil recovery (MEOR). In particular, the invention focuses on new, efficient, economical and environmentally safe microbial methods to enhance oil recovery in existing oil reservoirs, as well as microorganisms useful in such methods.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: Methods and kits are provided for screening a patient for bladder cancer. Embodiments include those involving centromeric probes to chromosomes 3, 7, and 10 and a locus-specific probe to 5p15.

Abstract: Methods for the rapid detection of the presence or absence of Hepatitis C Virus (HCV) in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers and probes targeting HCV and kits are provided that are designed for the detection of HCV.

Abstract: The invention provides novel BTNL9 proteins, including multimers, fragments, and variants of a human BTNL9 protein. In addition, antibodies that can bind to BTNL9 proteins and nucleic acids encoding BTNL9 proteins are provided. Uses for BTNL9 proteins, and agonists or antagonists thereof, are described.

Abstract: Disclosed herein are methods and compositions for targeted modification of one or more endogenous plant malate dehydrogenase genes.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: Aptamers that bind to and antagonize programmed cell death protein 1 (PD-1). Also provided herein are pharmaceutical compositions comprising such anti-PD-1 aptamers and methods for using the same for promoting T cell proliferation, treating cancer or infectious diseases, such as human immunodeficiency virus (HIV) infection.

Abstract: Disclosed herein are methods and kits for selectively amplifying, detecting or quantifying a DNA fragment with a specific end sequence, especially generated following restriction enzyme digestion. This method can be used, for example, to detect a hypomethylated DNA fragment. This methods and kits are especially useful in detecting or quantifying a hypomethylated fetal DNA fragment in a maternal plasma sample containing a corresponding hypermethylated maternal DNA fragment.

Abstract: The present disclosure describes improved SELEX methods for producing aptamers that are capable of binding to target molecules and improved photoSELEX methods for producing photoreactive aptamers that are capable of both binding and covalently crosslinking to target molecules. Specifically, the present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. In addition, the disclosure describes aptamer constructs that include a variety of functionalities, including a cleavable element, a detection element, and a capture or immobilization element.

Abstract: Provided is methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.